At the 10th Annual School of Nursing Oncology, faculty said nurses need fast, disease-specific updates to educate patients and manage novel therapies.
|Videos|June 22, 2019
Quality of Life Is an Important Endpoint in Cancer Trials
Author(s)Giuseppe Lombardi, MD, PhD
Health-related quality of life (QOL) is becoming an increasingly important endpoint in cancer clinical trials.
Advertisement
Health-related quality of life (QOL) is becoming an increasingly important endpoint in cancer clinical trials, explained Giuseppe Lombardi, MD, PhD, a medical oncologist at the Veneto Institute of Oncology in Padua, Italy.
It is important that clinicians can offer patients not only the chance of improved survival, but also to live well in the meantime. This is especially true for patients with glioblastoma, who can have decreased neurologic or physical functioning. To ensure this, cancer treatment centers should assemble multidisciplinary teams that involve psychosocial supports, therapists, and more.
Advertisement
Related to this article
An ONS review presented at EONS19 outlines 7 system-level employer strategies to curb oncology nurse burnout and improve retention.
A Columbia nurse scientist shares her takeaways from the 2026 ASCO Quality Care Symposium, from geriatric assessment to care across the age span.
In a 117-patient cohort, 35% waited over 60 days for neoadjuvant chemotherapy, most often because of added workup, second opinions or comorbidities.
Interviews with 15 young women with breast cancer show fertility preservation decisions unfold under time pressure and carry into survivorship.
Among 90 patients with ES-SCLC, all CRS in the outpatient cohort was grade 1, and no patient in any care model was readmitted.
At the 2026 National Summit on Hematologic Cancers, Kate Kennedy, MSN, APRN, flagged decisions where guidelines give nurses and APPs little direction.
Interim AYA-NAV data show most navigation components reached young patients with cancer as designed, though full sessions lagged during treatment.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Approves MSI Companion Diagnostic for Pembrolizumab in MSI-H Tumors
2
FDA Approves Durvalumab-Enfortumab Vedotin for Cisplatin-Ineligible MIBC
3
Evolving Multiple Myeloma Care: What Nurses Need to Know About an Innovative Treatment Approach in Subcutaneous Administration
4
SONO 2026: Nurses Remain the Front Line as Cancer Therapies Evolve
5